Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
published in: Lancet Oncology Commission
date of publication: 2011-07-23
language: English
main subject: chemotherapy, multicenter clinical trial, lung cancer
Cites articles 17
Date
Title
Article - wd:Q29620648